The Royal College of GPs has received information from NHS England that general practice will have a much earlier role in delivery of the Pfizer/BioNTech vaccine than originally anticipated
A letter from NHSE primary care director Nikki Kanani has been sent to all practices in England, but GPs will be involved initially through PCN groupings as the beginning of a general mobilisation of practices.
The RCGP will keep you updated with our full response as things develop and will be looking to produce resources to support GPs and their teams.
They will also be monitoring the situation for our members in Scotland, Wales and NI.
The College is truly grateful for everything GPs and their teams are doing to help the COVID effort. Their contribution throughout the pandemic has been magnificent.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events relating to CSL Seqirus products should also be reported to Seqirus UK Limited on 01748 828816.
1. Seqirus Data on File, August 2023. SREF–17994. 2. Adjuvanted Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics. 3. Cell-based Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
Be the first to comment